About Genprex
Genprex is a publicly listed company based in Austin (United States) founded in 2009. Therapeutics for molecular-level cancer treatment are developed. Genprex has raised $3.11 million across 9 funding rounds from investors including NIH and Inception Capital Management. The company has 15 employees. Its website genprex.com draws about 10 thousand monthly visits. Genprex offers products and services including Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is Genprex, Inc. Its competitors include Insulet, Kriya Therapeutics and Sana Biotechnology; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2009 and based in Austin, United States, operations in the biotechnology sector are focused on cancer therapeutics. Molecular-level treatments, including the lead candidate Oncoprex combined with erlotinib, are designed to induce apoptosis in cancer cells and regulate signaling and inflammatory pathways. These therapies target non-small cell lung cancer and metastases, with delivery via injection.
- Headquarters Austin, United States
- Employees 15
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website genprex.com
- Social LinkedIn X Facebook
- Legal Name Genprex, Inc.
- Net Profit-$16.23 M (USD)23.13as on Dec 31, 2025
- EBITDA-$15.52 M (USD)26.7as on Dec 31, 2025
- Total Equity Funding$3.11M (USD)
in 9 rounds
- Latest Funding Round$2.59M (USD), Grant
Jul 2020
- InvestorsNIH
& 1 more
- Employee Count15
Products & Services of Genprex
Genprex offers a comprehensive portfolio of products and services, including Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002.
System for delivering genes to treat cancer effectively
Therapy reintroducing genes to suppress tumors in patients
Treatment targeting cancer and diabetes through gene administration
Funding Insights of Genprex
Genprex has successfully raised a total of $3.11M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $2.59 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.11M
- Total Rounds 9
- Last Round Grant — $2.59M
- First Round $1.5M
(Dec 2013)
- Investors Count 2
All 9 funding rounds of Genprex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $2.59M | Grant | – | – | |
| May 2020 | $2.5M | Post-IPO | – | – | – |
| Feb 2020 | $17.5M | Post-IPO | – | – | – |
| Jan 2020 | $8M | Post-IPO | – | – | – |
| May 2018 | $10M | Post-IPO | – | – | – |
| Nov 2016 | $949,971 | Seed | – | Inception Capital Management | – |
| Mar 2015 | $160,000 | Seed | – | – | – |
| Dec 2013 | $500,000 | Seed | – | – | – |
| Dec 2013 | $1.5M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Genprex
Genprex has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH and Inception Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investments are directed toward US and Australia opportunities. | inceptionfunds.com | Kirkland, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Genprex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genprex
20 people are tracked at Genprex (8 in leadership, 4 in board & advisors, 8 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
William E. Gannon Jr. | VP, Regulatory Affairs | Leadership |
Mark S. Berger | Chief Medical Officer | Leadership |
Kate Combs | Senior Director of Clinical Operations | Leadership |
Rodney Varner | President & CEO | Leadership |
Kalyn D. | Director Of Communications | Leadership |
Ryan Confer | CFO | Leadership |
Pier-Anne Lachance | Associate Director Quality Control | Leadership |
Suzanne Thornton-Jones | Senior Vice President, Regulatory Affairs And Quality | Leadership |
Jose A. Moreno Toscano | Director | Board & advisors |
William Wilson | Director | Board & advisors |
James E. Rothman | Strategic Advisor | Board & advisors |
Brent Longnecker | Director | Board & advisors |
Greg Jancarik | Corporate Controller | Team |
Sarah Nguyen | Senior Manager of Quality Assurance Operations | Team |
David M. Schloss | SVP, HR | Team |
Edith Gastelum | Clinical Research Associate II | Team |
Thomas Gallagher | SVP, Intellectual Property & Licensing | Team |
Kalyn Dabbs | Senior Manager of Communications & Marketing | Team |
Eileen Freund | Executive Assistant, Legal & Project Management | Team |
Gina Johnson | QC Manager Stability & Product Lifecycle Management | Team |
Complete people profiles for Genprex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genprex
Genprex is a publicly listed company on the NASDAQ with ticker symbol GNPX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Mar 2018
- Listed onNASDAQ: GNPX
- Listed entityGenprex, Inc.
- Exchange sectorHealth technology
- ISINUS3724464017
- Share price$2.51 (-6.69% on the day) · 2026-10-13
- Market capitalisation$2.1M
- EPS (diluted, trailing year)$-158.75
- Volume (last session)170,803
Financials of Genprex
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$16.2M | -$15.5M | |
| 2024 | -$21.1M | -$21.2M | |
| 2023 | -$30.9M | -$31.1M | |
| 2022 | -$23.7M | -$23.8M | |
| 2021 | -$20.7M | -$20.6M |
Detailed financial statements for Genprex
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Genprex
4 dated milestones of Genprex across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Genprex is founded.
- Funding First funding round of $1.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $2.6M.
Competitors of Genprex
Genprex has 3 listed competitors in our database, 3 of them funded. They include Insulet, Kriya Therapeutics and Sana Biotechnology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insulet.com | 2000 | Boston, United States | $120.4M | 2,600 | Wearable insulin infusion systems are developed for diabetes patients. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. |
Detailed competitors of Genprex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genprex
The website of Genprex (genprex.com) receives about 10.3K visits a month and ranks #2,016,023 among all websites worldwide, #2,748 in Biotechnology and Pharmaceuticals.
- Monthly visits10.3K
▼ 5.5% vs previous month
- Unique visitors5K
per month
- Global rank#2,016,023
among all websites
- Category rank#2,748
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit2.0
- Average visit27 sec
- DevicesDesktop 24% · Mobile 76%
Websites whose visitors overlap most with Genprex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novocure.com | 100% | 37.8K | #872,540 | View details | |
| foundationmedicine.com | 99% | 65K | #611,310 | View details | |
| biodesix.com | 99% | 7.4K | #2,413,737 | View details | |
iaslc.org | iaslc.org | 77% | #558,107 | – | |
browncancercenter.org | browncancercenter.org | 64% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Genprex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Genprex (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genprex
Complete news archive for Genprex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genprex
Genprex was founded in 2009 and raised its 1st funding round 4 years after it was founded.
Genprex is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Genprex is a funded company, having raised a total of $3.11M across 9 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Dec 2013.
Genprex has 15 employees.
Founded in 2009 and based in Austin, United States, operations in the biotechnology sector are focused on cancer therapeutics. Molecular-level treatments, including the lead candidate Oncoprex combined with erlotinib, are designed to induce apoptosis in cancer cells and regulate signaling and inflammatory pathways. These therapies target non-small cell lung cancer and metastases, with delivery via injection.
Genprex's top competitors include Insulet, Sana Biotechnology and Kriya Therapeutics.
Genprex offers Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002.
Yes, Genprex is publicly traded on NASDAQ under the ticker symbol GNPX.
Genprex has 2 investors. Key investors include NIH, and Inception Capital Management.
Genprex operates through Genprex, Inc..